X-Linked Combined Immunodeficiency Diseases clinical trials
The registry lists 28 studies for X-Linked Combined Immunodeficiency Diseases across more than 10 countries. 9 are recruiting or about to start. 16 of them are mainly about X-Linked Combined Immunodeficiency Diseases (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
Get an email when these change. Save the X-Linked Combined Immunodeficiency Diseases studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (8) · National Human Genome Research Institute (NHGRI) (3) · Great Ormond Street Hospital for Children NHS Foundation Trust (2) · David Williams (2) · Phenox GmbH (2) · New York Medical College (1) · University of Miami (1) · Shenzhen Geno-Immune Medical Institute (1)
What is being tested here
Drugs under test in X-Linked Combined Immunodeficiency Diseases studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Busulfan | 1 | 0 | 3 |
| Fibroblast Growth Factor 7 | 1 | 0 | 2 |
| Alemtuzumab | 1 | 0 | 2 |
| Filgrastim | 1 | 0 | 1 |
| Cyclosporine | 0 | 0 | 1 |
| Mycophenolic Acid | 0 | 0 | 1 |
| Mecasermin | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Nov 2026Early Check: Expanded Screening in Newborns · RTI International
Who these studies take
Of the 6 X-Linked Combined Immunodeficiency Diseases studies recruiting now, 2 (33%) set no upper age limit and 4 (67%) stop at 75 or younger. 6 (100%) take children under 18. 0 (0%) are for women only and 4 (67%) for men only; 1 (17%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (33%) | 4 (67%) |
| 18 | 2 (33%) | 4 (67%) |
| 30 | 2 (33%) | 3 (50%) |
| 40 | 2 (33%) | 3 (50%) |
| 50 | 2 (33%) | 3 (50%) |
| 65 | 2 (33%) | 2 (33%) |
| 75 | 2 (33%) | 2 (33%) |
| 85 | 2 (33%) | 2 (33%) |
Across all 28 studies, recruiting or not: 61% stop at 75 or younger and 61% at 65; 96% take children; 4% are for women only and 36% for men only; 7% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 28 of 28. search them.
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)RecruitingNCT01306019Phase 1/21 country
- Evaluation of Patients With Immune Function AbnormalitiesRecruitingNCT001289731 country
- SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) InjectionNot yet recruitingNCT03217617Phase 1/21 country
- Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene TherapyEnrolling by invitationNCT06851767Phase 1/21 country
- Targeting Real World Usage In Stroke TreatmentRecruitingNCT074749355 countries
- Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan ConditioningRecruitingNCT03311503Phase 1/21 country
- Lentiviral Gene Therapy for X-linked Severe Combined ImmunodeficiencyRecruitingNCT03601286Phase 11 country
- Natural History Study of SCID DisordersEnrolling by invitationNCT011869132 countries
- Gene Therapy for X Linked Severe Combined ImmunodeficiencyRecruitingNCT04286815Not applicable1 country
- Early Check: Expanded Screening in NewbornsActive, not recruitingNCT036552231 country
- Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral VectorCompletedNCT01129544Phase 1/21 country
- Gene Therapy for X-linked Severe Combined ImmunodeficiencyCompletedNCT01410019Phase 1/21 country
- Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed InfantsSuspendedNCT01512888Phase 1/21 country
- Molecular and Clinical Studies of Primary Immunodeficiency DiseasesActive, not recruitingNCT000063191 country
- Human Placental-Derived Stem Cell TransplantationCompletedNCT01586455Phase 11 country
- Diversion-p64 Post Market Clinical Follow-Up Study to Assess Safety and Effectiveness of the p64 Flow Modulation DeviceCompletedNCT0260036410 countries
- Patients Treated for SCID (1968-Present)Status unknownNCT013461502 countries
- Multi-center Clinical Study of Cord Blood Stem Cell Transplantation for SCIDStatus unknownNCT041721811 country
- Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined ImmunodeficiencyStatus unknownNCT03315078Phase 1/21 country
- Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow TransplantCompletedNCT00008450Phase 11 country
- cliniMACs HUD for T Cell DepletionNo longer availableNCT029154061 country
- Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1)Status unknownNCT01175239Not applicable1 country
- Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCIDCompletedNCT000063351 country
- Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID)CompletedNCT00028236Phase 11 country
- Developing Newborn Screening for Infants With Primary ImmunodeficiencyCompletedNCT001134641 country
- Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1TerminatedNCT00490100Phase 1/21 country
- Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency DisordersTerminatedNCT00579137Phase 1/21 country
- A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant DisordersStatus unknownNCT005969991 country